Trial description:
A Phase 3, Randomized Open-label Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castrationresistant Prostate Cancer (mCRPC) Who are Unselected for Homologous Recombination Repair Defects and Have Failed Prior Treatment with One Next generation Hormonal Agent (NHA) and Chemotherapy
Contact name:
Dr Danish Mazhar
Trial start date:
Tuesday, September 24, 2019
Trial end date:
Wednesday, December 30, 2020
Trial tumour type:
Prostate
Show on Radiotherapy:
No
